Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
Bristol-Myers Squibb
PrECOG, LLC.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Pfizer
University of Maryland, Baltimore
Taiho Oncology, Inc.
Regeneron Pharmaceuticals
NRG Oncology
Big Ten Cancer Research Consortium
Mayo Clinic
Jiangsu HengRui Medicine Co., Ltd.
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
BeiGene
Masonic Cancer Center, University of Minnesota
Mirati Therapeutics Inc.
Ohio State University Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Avistone Biotechnology Co., Ltd.
Bristol-Myers Squibb
Fundación GECP
Checkpoint Therapeutics, Inc.
EpicentRx, Inc.
Novartis
Massachusetts General Hospital
BeiGene
NantCell, Inc.
Sichuan University
EpicentRx, Inc.